LabTurbo Biotech

Executive Summary

LabTurbo Biotech is a Taiwan-based molecular diagnostics company specializing in fully automated nucleic acid extraction and real-time PCR platforms, along with validated reagent kits and multiplex panels for infectious disease testing. Founded in 2020 and publicly traded, the company has achieved commercial-stage operations with integrated hardware-software-reagent solutions that enable high-throughput, hands-off workflows for clinical and research laboratories. LabTurbo's focus on automation and workflow efficiency positions it to capitalize on the growing demand for decentralized, rapid infectious disease diagnostics, particularly in Asia-Pacific and emerging markets. The company's platform offers advantages in reducing hands-on time and cross-contamination risk, targeting applications in hospital labs, reference centers, and public health settings. While the diagnostics market is competitive, LabTurbo's proprietary technology and existing commercial traction provide a foundation for growth, though revenue scale and profitability remain unconfirmed from available data.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance for respiratory panel70% success
• Q3 2026Partnership with major hospital group in Southeast Asia60% success